Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 4, 2008, Pages 321-326

  Hillman, L C ^a,b,c,d   Chiragakis, L ^a   Shadbolt, B ^b,c   Kaye, G L ^a   Clarke, A C ^a  

^a Mugga Wara and Brindabella Endoscopy Centres ^*

^b CANBERRA HOSPITAL   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^d Mugga Wara/Brindabella Endoscopy Ctr   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; DYSPLASIA; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; INCIDENCE; MALE; METAPLASIA; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; PROTON PUMPS; TREATMENT OUTCOME;

EID: 38149050433     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03579.x     Document Type: Article

References (29)

1. Dent J, Bremner CG, Collen MJ, Haggitt RC, Spechler SJ. Working Party Report to the World Congresses of Gastroenterology, Sydney 1990. Barrett's oesophagus. J Gastroenterol Hepatol 1991 6:1 22.
2. Sampliner RE the Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's oesophagus. Am J Gastroenterol 1998 93:1028 32.
3. Nandurkar S, Talley NJ. Surveillance in Barrett's oesophagus: a need for reassessment? J Gastroenterol Hepatol 1998 13:990 6.
4. Hillman LC, Chiragakis L, Clarke AC, et al. Barrett's oesophagus: macroscopic markers and the prediction of dysplasia and adenocarcinoma. J Gastroenterol Hepatol 2003 18:526 33.
5. Falk GW. Barrett's oesophagus. Gastroenterology 2002 122:1569 91.
6. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000 321:1252 5.
7. van Blankenstein M. Barrett's oesophagus: so what! Dis Esophagus 2002 15:1 4.
8. van der Burgh A, Dees J, Hop WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996 39:5 8.
9. Buttar NS, Wang KK, Sebe TJ, et al. Extent of high-grade dysplasia in Barrett's oesophagus correlates with risk of adenocarcinoma. Gastroenterology 2001 120:1630 9.
10. Stolte M, Vieth M, Schmitz JM, et al. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus. Scand J Gastroenterol 2000 35:1125 30.
11. Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996 111:85 92.
12. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's oesophagus: the AGA Chicago workshop. Gastroenterology 2004 127:310 30.
13. Weinstein M. The prevention and treatment of dysplasia in gastroesophageal reflux disease: the results and challenges ahead. J Gastroenterol Hepatol 2002 17:S113 24.
14. Umansky M, Yasui W, Hallak A, et al. Proton pump inhibitors reduce cell cycle anomalies in Barrett's esophagus. Oncogene 2001 20:7987 91.
15. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's oesophagus and the effects of acid suppression. Gastroenterology 1999 117:327 35.
16. Fennerty MB, Triadafilopoulos G. Barrett's related adenocarcinoma: is chemoprevention a potential option? Am J Gastroenterol 2001 96:2302 5.
17. Peters FTM, Ganesh S, Kuipers EJ, et al. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett oesophagus. Scand J Gastroenterol 2000 12:1239 44.
18. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004 180:387 91.
19. El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's oesophagus. Am J Gastroenterol 2004 99:1877 83.
20. Koop H. Gastroesophageal reflux disease and Barrett's oesophagus. Endoscopy 2002 34:97 103.
21. Hofstetter WL, Peters JH, DeMeester TR, et al. Long-term outcome of antireflux surgery in patients with Barrett's oesophagus. Ann Surg 2001 234:532 9.
22. Chen L, Hu C, Gabeury L, et al. Proliferative activity in Barrett's oesophagus before and after antireflux surgery. Ann Surg 2001 234:172 80.
23. Peters JH, Clark GWB, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's oesophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994 108:813 22.
24. Csendes A, Burdiles P, Braghetto I, Korn O. Adenocarcinoma appearing very late after antireflux surgery for Barrett's oesophagus: long-term follow-up, review of the literature, and addition of six patients. J Gastrointestinal Surg 2004 8:434 41.
25. El-Serag HB, Aguirre T, Kubeler M, Sampliner RE. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy. Aliment Pharmacol Ther 2004 19:1255 60.
26. Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's oesophagus. Gastroenterology 2002 122:299 307.
27. Feagins LA, Zhang HY, Hormi-Carver K, et al. Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 2007 102:10 20.
28. Zhang HY, Zhang X, Hormi-Carver K, et al. In non-neoplastic Barrett's epithelial cells, acid exerts antiproliferative effects through activation of the Chk2 pathway. Cancer Res 2007 67:8580 7.
29. Leedham S, Jankowski J. The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus - the good, the bad, and the flawed. Am J Gastroenterol 2007 102:21 3.